Definium Therapeutics, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Jarvis is thinking

Definium Therapeutics, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Income Statement

	2025-12-31	2024-12-31
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$166.31M	-$103.92M
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$183.79M	-$108.68M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-2.06	$-1.54
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-2.06	$-1.54

Balance Sheet

	2025-12-31	2024-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$257.84M	$273.74M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$440.10M	$302.15M
Everything the company owes — debt, unpaid bills, and other obligations.	$107.77M	$60.70M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$332.33M	$241.45M

Cash Flow Statement

	2025-12-31	2024-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$131.56M	-$79.13M

Peer Comparison

	You	Peer avg
P/E	–	38.3
Revenue Growth	–	+628.8%
ROE	-64.1%	186.2%